Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irofulven vs 5-FU in Gemcitabine-Refractory Pancreatic Cancer
NCT00033735Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2000
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irofulven in pancreatic ductal adenocarcinoma (PDAC), sponsored by Eisai Co., Ltd.. Started Jan 2000; status: completed.
02
Drugs
irofulven
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00033735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033735.